Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous MGMT P140K-transduced hematopoietic stem cells (Fred Hutch)
- Development stage
- Unknown
- Lead developer
- Fred Hutchinson Cancer Center
- Modality
- Stem Cell Therapies → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Autologous transduced hematopoietic cells developed by Fred Hutchinson Cancer Center is an experimental ex vivo gene therapy for the treatment of HIV-associated Hodgkin and non-Hodgkin lymphoma. The therapy involves the collection of a patient's own peripheral blood stem cells, which are then genetically modified using a lentiviral vector to express a gene conferring HIV resistance and a mutant form of the O6-methylguanine-DNA methyltransferase (MGMT P140K) gene. Following high-dose chemotherapy and autologous transplantation of these modified cells, patients receive treatment with O6-benzylguanine (O6BG) and carmustine (BCNU). The MGMT P140K mutation protects the modified cells from the toxic effects of this combination, allowing for the in vivo enrichment of the HIV-resistant cell population. This approach aims to reconstitute the immune system with cells that are refractory to HIV infection while simultaneously treating the underlying lymphoma.
- Other names
- MGMT P140K-transduced HSCsHIV-resistant hematopoietic stem cell therapy
Beyond the preview
Go deeper on autologous MGMT P140K-transduced hematopoietic stem cells (Fred Hutch).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous MGMT P140K-transduced hematopoietic stem cells (Fred Hutch).